Roivant Sciences (ROIV) Short-Term Debt issuances (2020 - 2022)
Roivant Sciences' (ROIV) quarterly Short-Term Debt issuances came in at $159.9 million in Q4 2022, up 339.28% YoY from $36.4 million in Q4 2021, and little changed on a QoQ basis from $159.9 million in Q2 2022.
Roivant Sciences (ROIV) Short-Term Debt issuances (2020 - 2022) Analysis & Trends
Roivant Sciences (ROIV) has 3 years of Short-Term Debt issuances data on file, last reported at $159.9 million in Q4 2022.
- Quarterly Short-Term Debt issuances rose 339.28% year-over-year to $159.9 million in Q4 2022, while the trailing twelve-month figure through Dec 2023 was $159.9 million (down 55.11% YoY) and the FY2023 annual result came in at $159.9 million, up 339.28% from the prior year.
- Short-Term Debt issuances was little changed at $159.9 million in Q4 2022, from $159.9 million in the prior quarter.
- In the past five years, Short-Term Debt issuances ranged from a high of $159.9 million in Q2 2022 to a low of -$36.4 million in Q4 2020.
- A 3-year average of $71.2 million and a median of $36.4 million in 2021 frame the typical range for Short-Term Debt issuances.
- Annual changes were most pronounced in 2021 — Short-Term Debt issuances surged 200.0% — and 2022, when it soared 339.28%.
- Tracing ROIV's Short-Term Debt issuances over 3 years: stood at -$36.4 million in 2020, then surged by 200.0% to $36.4 million in 2021, then surged by 339.28% to $159.9 million in 2022.
- The last three Short-Term Debt issuances figures came in at $159.9 million (Q4 2022), $159.9 million (Q2 2022), and $36.4 million (Q4 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 159.90 Mn |
| Dec 31, 2022 | 159.90 Mn |
| Jun 30, 2022 | 159.90 Mn |
| Jun 30, 2022 | 159.90 Mn |
| Dec 31, 2021 | 36.40 Mn |
| Dec 31, 2021 | 36.40 Mn |
| Jun 30, 2021 | 36.40 Mn |
| Jun 30, 2021 | 36.40 Mn |
| Dec 31, 2020 | -36.40 Mn |
| Dec 31, 2020 | -36.40 Mn |